Hypoxia inducible factor 2Α (hif-2Α)

Clinical trials for Hypoxia inducible factor 2Α (hif-2Α) explained in plain language.

Never miss a new study

Get alerted when new Hypoxia inducible factor 2Α (hif-2Α) trials appear

Sign up with your email to follow new studies for Hypoxia inducible factor 2Α (hif-2Α), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New pill shows promise for Hard-to-Treat kidney cancer

Disease control Stopped early

This study tested an oral drug called NKT2152 in people with advanced clear cell renal cell carcinoma that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, but the data may still help guid…

Matched conditions: HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α)

Phase 1/2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:57 UTC

Hypoxia inducible factor 2Α (hif-2Α)

Get alerted when new Hypoxia inducible factor 2Α (hif-2Α) trials appear

New pill shows promise for Hard-to-Treat kidney cancer